Oczyesa (Octreotide)

Octreotide, the active ingredient in Oczyesa, is a synthetic somatostatin analog presented as an injectable solution for subcutaneous or intravenous use. It regulates hormone secretion and reduces splanchnic blood flow, making it useful in adults with specific endocrine and gastrointestinal disorders.

GNH USA supplies Oczyesa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Octreotide acts on somatostatin receptors to control hormone‑driven conditions and bleeding disorders. - Acromegaly: reduces excessive growth hormone secretion and lowers serum IGF‑1 levels. - Carcinoid syndrome: diminishes flushing and diarrhea by inhibiting serotonin release. - VIPoma (vasoactive intestinal peptide tumor): controls severe watery diarrhea and electrolyte loss. - Bleeding from esophageal varices: decreases portal venous pressure and limits acute hemorrhage.

Octreotide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Abdominal pain: cramping or discomfort after injection. - Diarrhea: loose stools, often transient. - Injection site reactions: redness, swelling, or bruising. - Hyperglycemia: elevated blood glucose levels. - Gallstones: formation of biliary sludge or stones.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypoglycemia: dangerously low blood glucose. - Cardiac arrhythmias: irregular heart rhythms. - Anaphylaxis: life‑threatening allergic reaction. - Hepatic dysfunction: abnormal liver function tests. - Severe gallbladder disease: cholecystitis or biliary colic.

Octreotide requires careful monitoring and patient education before use. - Glucose monitoring: assess blood sugar regularly, especially in diabetics. - Gallbladder assessment: perform ultrasound if symptomatic to detect stones. - Cardiac evaluation: monitor ECG in patients with known heart disease. - Renal/hepatic impairment: adjust dosing or monitor closely in dysfunction. - Hypersensitivity: avoid if known allergy to octreotide or formulation components. - Store at ambient temperature: keep in original container, protect from moisture and light.

Octreotide can alter the pharmacokinetics of several medicines.

Major Interactions (Avoid): - Cyclosporine: increased cyclosporine levels may cause nephrotoxicity. - Quinidine: octreotide can raise quinidine concentrations, risking arrhythmias. - Insulin: may mask hypoglycemia symptoms, requiring dose adjustment.

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced efficacy, consider alternative contraception. - Antidiabetic agents: may require dose changes due to altered glucose control. - Digoxin: possible changes in serum levels, monitor therapeutic range.